tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

VALN Stock Latest News

Valneva Announces Positive Phase 2 Results for Chikungunya Vaccine in Children
Company AnnouncementsValneva Announces Positive Phase 2 Results for Chikungunya Vaccine in Children
3d ago
6K
VALN
Valneva says IXCHIQ ‘well tolerated’ by children ages 1-11 years
PremiumThe Fly
Valneva says IXCHIQ ‘well tolerated’ by children ages 1-11 years
4d ago
VALN
Valneva Prepares for Shareholder Meeting and Announces Leadership Change
PremiumCompany Announcements
Valneva Prepares for Shareholder Meeting and Announces Leadership Change
5d ago
6K
VALN
Valneva to Engage with Investors at June Conferences
PremiumCompany Announcements
Valneva to Engage with Investors at June Conferences
13d ago
6K
VALN
Valneva’s Chikungunya Vaccine Use Paused for Elderly Amid Safety Review
PremiumCompany Announcements
Valneva’s Chikungunya Vaccine Use Paused for Elderly Amid Safety Review
27d ago
6K
VALN
Valneva price target lowered to $14 from $15 at Guggenheim
PremiumThe FlyValneva price target lowered to $14 from $15 at Guggenheim
1M ago
VALN
Valneva SE Reports Strong Q1 2025 Revenue Growth
Premium
Company Announcements
Valneva SE Reports Strong Q1 2025 Revenue Growth
1M ago
VALN
Valneva Reports Strong Q1 2025 Results and Advances Vaccine Portfolio
Premium
Company Announcements
Valneva Reports Strong Q1 2025 Results and Advances Vaccine Portfolio
1M ago
6K
VALN
Valneva says EMA started Ixchiq review after reports of SAEs
PremiumThe Fly
Valneva says EMA started Ixchiq review after reports of SAEs
1M ago
VALN
Valneva’s Chikungunya Vaccine Use Suspended for Elderly Amid Safety Concerns
PremiumCompany Announcements
Valneva’s Chikungunya Vaccine Use Suspended for Elderly Amid Safety Concerns
1M ago
6K
VALN
Valneva’s Chikungunya Vaccine Receives Updated ACIP Recommendation Amid Safety Review
PremiumCompany Announcements
Valneva’s Chikungunya Vaccine Receives Updated ACIP Recommendation Amid Safety Review
2M ago
6K
VALN
Valneva Showcases Chikungunya Vaccine at World Vaccine Congress
PremiumCompany Announcements
Valneva Showcases Chikungunya Vaccine at World Vaccine Congress
2M ago
6K
VALN
Valneva’s Vaccine Approval and Strategic Partnerships Drive Buy Rating with Promising Financial Projections
PremiumRatingsValneva’s Vaccine Approval and Strategic Partnerships Drive Buy Rating with Promising Financial Projections
2M ago
VALN
Valneva’s Chikungunya Vaccine Gains First Approval in Brazil
Premium
Company Announcements
Valneva’s Chikungunya Vaccine Gains First Approval in Brazil
2M ago
6K
VALN
Valneva granted marketing authorization for Ixchiq in Brail
Premium
The Fly
Valneva granted marketing authorization for Ixchiq in Brail
2M ago
VALN
Positive Outlook for Valneva Driven by Promising Vaccine Pipeline and Strategic Developments
PremiumRatings
Positive Outlook for Valneva Driven by Promising Vaccine Pipeline and Strategic Developments
2M ago
VALN
Valneva and LimmaTech Initiate Phase 2 Study of Shigella Vaccine
PremiumCompany Announcements
Valneva and LimmaTech Initiate Phase 2 Study of Shigella Vaccine
2M ago
6K
VALN
Valneva’s Chikungunya Vaccine Gains EU Approval for Adolescents
PremiumCompany Announcements
Valneva’s Chikungunya Vaccine Gains EU Approval for Adolescents
2M ago
6K
VALN
Valneva granted EC marketing authorization for Ixchiq vaccine
PremiumThe Fly
Valneva granted EC marketing authorization for Ixchiq vaccine
2M ago
VALN
Valneva’s Strategic Advancements and Promising Projections Drive Buy Rating with $17 Target
PremiumRatingsValneva’s Strategic Advancements and Promising Projections Drive Buy Rating with $17 Target
2M ago
VALN
Valneva Seeks UK Approval for Adolescent Use of Chikungunya Vaccine
Premium
Company Announcements
Valneva Seeks UK Approval for Adolescent Use of Chikungunya Vaccine
2M ago
6K
VALN
Valneva renews sales agreement in connection with existing at-the-market program
Premium
The Fly
Valneva renews sales agreement in connection with existing at-the-market program
2M ago
VALN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >